- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Lexicon Pharmaceuticals Inc
+ Add to WatchlistLXRX:US
2.2100 USD 0.0300 1.38%As of 20:10:00 ET on 05/17/2013.
Snapshot for Lexicon Pharmaceuticals Inc (LXRX)
| Open: | 2.1800 | Day's Range: | 2.1300 - 2.2300 | Volume: | 996,287 |
|---|---|---|---|---|---|
| Previous Close: | 2.1800 | 52wk Range: | 1.4700 - 3.2800 | 1-Yr Rtn: | +46.36% |
Key Statistics for LXRX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.2100 |
| Est. EPS (USD) (12/2013) | -0.1820 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,133.79 |
| Shares Outstanding (M) | 513.03 |
| 30 Day Average Volume | 909,172 |
| Price/Book (mrq) | 4.6810 |
| Price/Sale (ttm) | 958.7279 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LXRX
Company Profile & Key Executives for LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease.
| Arthur T SandsPresident/CEO/Co-Founder | Jeffrey L WadeExec VP:Corporate Dev/CFO |
| Pablo LapuertaExec VP:Clinical Dev | Brian P ZambrowiczExec VP/Chief Scientific Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
LXRX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page